Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Recent Research Trends Against Skin Carcinoma - An Overview

In Press, (this is not the final "Version of Record"). Available online 24 July, 2024
Author(s): Kamya Varshney, Rupa Mazumder*, Anjna Rani, Rashmi Mishra and Navneet Khurana
Published on: 24 July, 2024

DOI: 10.2174/0113816128307653240710044902

Price: $95

Abstract

Skin cancer is a prevalent and sometimes lethal cancer that affects a wide range of people. UV radiation exposure is the main cause of skin cancer. Immunosuppression, environmental factors, and genetic predisposition are other contributing variables. Fair-skinned people and those with a history of sunburns or severe sun exposure are more likely to experience this condition. Melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) are the three main forms. Melanoma poses a bigger hazard because of its tendency for metastasis, while SCC and BCC have limited metastatic potential. Genetic mutations and changes to signalling pathways such as p53 and MAPK are involved in pathogenesis. Early diagnosis is essential, and molecular testing, biopsy, dermoscopy, and visual inspection can all help. In addition to natural medicines like curcumin and green tea polyphenols, treatment options include immunotherapy, targeted therapy, radiation, surgery, and chemotherapy. Reducing the incidence of skin cancer requires preventive actions, including sun protection and early detection programs. An overview of skin cancers, including their forms, pathophysiology, diagnosis, and treatment, highlighting herbal therapy, is given in this review.

[1]
Di Meglio P, Perera GK, Nestle FO. The multitasking organ: Recent insights into skin immune function. Immunity 2011; 35(6): 857-69.
[http://dx.doi.org/10.1016/j.immuni.2011.12.003] [PMID: 22195743]
[2]
Kashyap MP, Sinha R, Mukhtar MS, Athar M. Epigenetic regulation in the pathogenesis of non-melanoma skin cancer. Semin Cancer Biol 2022; 83: 36-56.
[http://dx.doi.org/10.1016/j.semcancer.2020.11.009] [PMID: 33242578]
[3]
Didona D, Paolino G, Bottoni U, Cantisani C. Nonmelanoma skin cancer pathogenesis overview. Biomedicines 2018; 6(1): 6.
[http://dx.doi.org/10.3390/biomedicines6010006] [PMID: 29301290]
[4]
Cockerell CJ. The pathology of melanoma. Dermatol Clin 2012; 30(3): 445-68.
[http://dx.doi.org/10.1016/j.det.2012.04.007] [PMID: 22800551]
[5]
Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: Epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther 2017; 7(S1) (Suppl. 1): 5-19.
[http://dx.doi.org/10.1007/s13555-016-0165-y] [PMID: 28150105]
[6]
Fernandes AR, Santos AC, Sanchez-Lopez E, et al. Neoplastic multifocal skin lesions: Biology, etiology, and targeted therapies for nonmelanoma skin cancers. Skin Pharmacol Physiol 2018; 31(2): 59-73.
[http://dx.doi.org/10.1159/000479529] [PMID: 29262420]
[7]
Rojas KD, Perez ME, Marchetti MA, Nichols AJ, Penedo FJ, Jaimes N. Skin cancer: Primary, secondary, and tertiary prevention. Part II. J Am Acad Dermatol 2022; 87(2): 271-88.
[http://dx.doi.org/10.1016/j.jaad.2022.01.053] [PMID: 35176398]
[8]
Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006; 55(5): 741-60.
[http://dx.doi.org/10.1016/j.jaad.2005.08.063] [PMID: 17052479]
[9]
Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol 2017; 76(4): 639-647.e2.
[http://dx.doi.org/10.1016/j.jaad.2016.09.047] [PMID: 27876302]
[10]
Balda A, Wani I, Roohi TF, et al. Psoriasis and skin cancer – Is there a link? Int Immunopharmacol 2023; 121: 110464.
[http://dx.doi.org/10.1016/j.intimp.2023.110464] [PMID: 37390565]
[11]
Fahradyan A, Howell A, Wolfswinkel E, Tsuha M, Sheth P, Wong A. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare 2017; 5(4): 82.
[http://dx.doi.org/10.3390/healthcare5040082] [PMID: 29104226]
[12]
Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: The pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012; 122(2): 464-72.
[http://dx.doi.org/10.1172/JCI57415] [PMID: 22293185]
[13]
Kasper M, Jaks V, Hohl D, Toftgård R. Basal cell carcinoma - molecular biology and potential new therapies. J Clin Invest 2012; 122(2): 455-63.
[http://dx.doi.org/10.1172/JCI58779] [PMID: 22293184]
[14]
Sánchez-Danés A, Blanpain C. Deciphering the cells of origin of squamous cell carcinomas. Nat Rev Cancer 2018; 18(9): 549-61.
[http://dx.doi.org/10.1038/s41568-018-0024-5] [PMID: 29849070]
[15]
Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: A review of high-risk and metastatic disease. Am J Clin Dermatol 2016; 17(5): 491-508.
[http://dx.doi.org/10.1007/s40257-016-0207-3] [PMID: 27358187]
[16]
Farberg AS, Marson JW, Glazer A, et al. Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: Consensus from the skin cancer prevention working group. Dermatol Ther 2022; 12(4): 807-23.
[http://dx.doi.org/10.1007/s13555-022-00709-x] [PMID: 35353350]
[17]
Cives M, Mannavola F, Lospalluti L, et al. Non-melanoma skin cancers: Biological and clinical features. Int J Mol Sci 2020; 21(15): 5394.
[http://dx.doi.org/10.3390/ijms21155394] [PMID: 32751327]
[18]
Di Stefani A, Chimenti S. Societa italiana di dermatologia e sifilografia. Basal cell carcinoma: Clinical and pathological features. Soc Ital Dermat Sifilografia 2015; 150(4): 385-91.
[19]
Abbas O, Richards JE, Mahalingam M. Fibroblast-activation protein: A single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol 2010; 23(11): 1535-43.
[http://dx.doi.org/10.1038/modpathol.2010.142] [PMID: 20711172]
[20]
Betti R, Menni S, Radaelli G, Bombonato C, Crosti C. Micronodular basal cell carcinoma: A distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol 2010; 37(7): 611-6.
[http://dx.doi.org/10.1111/j.1346-8138.2009.00772.x] [PMID: 20629826]
[21]
Tan CZ, Rieger KE, Sarin KY. Basosquamous carcinoma: Controversy, advances, and future directions. Dermatol Surg 2017; 43(1): 23-31.
[http://dx.doi.org/10.1097/DSS.0000000000000815] [PMID: 27340741]
[22]
Dennis LK, White E, Lee JAH. Recent cohort trends in malignant melanoma by anatomic site in the United States. Cancer Causes Control 1993; 4(2): 93-100.
[http://dx.doi.org/10.1007/BF00053149] [PMID: 8481498]
[23]
Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer 2022; 22(1): 836.
[http://dx.doi.org/10.1186/s12885-022-09940-3] [PMID: 35907848]
[24]
Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet 2018; 392(10151): 971-84.
[http://dx.doi.org/10.1016/S0140-6736(18)31559-9] [PMID: 30238891]
[25]
Evans RD, Kopf AW, Lew RA, et al. Risk factors for the development of malignant melanoma: Review of case-control studies. J Dermatol Surg Oncol 1988; 14(4): 393-408.
[http://dx.doi.org/10.1111/j.1524-4725.1988.tb03373.x] [PMID: 3280634]
[26]
Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25(6): 459-63.
[http://dx.doi.org/10.1046/j.1365-2230.2000.00693.x] [PMID: 11044179]
[27]
Roomi MW, Roomi NW, Kalinovsky T, Ivanov V, Rath M, Niedzwiecki A. Inhibition of 7,12-dimethylbenzanthracene-induced skin tumors by a nutrient mixture. Med Oncol 2008; 25(3): 333-40.
[http://dx.doi.org/10.1007/s12032-008-9041-7] [PMID: 18204975]
[28]
Pinchuk I, Shoval H, Dotan Y, Lichtenberg D. Evaluation of antioxidants: Scope, limitations and relevance of assays. Chem Phys Lipids 2012; 165(6): 638-47.
[http://dx.doi.org/10.1016/j.chemphyslip.2012.05.003] [PMID: 22721987]
[29]
The Fitzpatrick Skin Type Classification Scale. 2008. Available from: https://www.skininc.com/science/physiology/article/ 21882228/the-fitzpatrick-skin-type-classification-scale(accessed on 13-6-2024)
[30]
Fitzpatrick TB. Ultraviolet-induced pigmentary changes: Benefits and hazards. Curr Probl Dermatol 1986; 15: 25-38.
[http://dx.doi.org/10.1159/000412090] [PMID: 3512179]
[31]
Perez L. Diagnosis and management of nonmelanoma skin cancer. Osteopath Family Phys 2020; 12(3): 30-4.
[http://dx.doi.org/10.33181/12032]
[32]
Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept 2017; 7(2): 1-6.
[http://dx.doi.org/10.5826/dpc.0702a01] [PMID: 28515985]
[33]
Lewis KG, Weinstock MA. Nonmelanoma skin cancer mortality (1988-2000): The Rhode Island follow-back study. Arch Dermatol 2004; 140(7): 837-42.
[http://dx.doi.org/10.1001/archderm.140.7.837] [PMID: 15262694]
[34]
Doran CM, Ling R, Byrnes J, et al. Benefit cost analysis of three skin cancer public education mass-media campaigns implemented in New South Wales, Australia. PLoS One 2016; 11(1): e0147665.
[http://dx.doi.org/10.1371/journal.pone.0147665] [PMID: 26824695]
[35]
Reichrath J, Saternus R, Vogt T. Endocrine actions of vitamin D in skin: Relevance for photocarcinogenesis of non-melanoma skin cancer, and beyond. Mol Cell Endocrinol 2017; 453: 96-102.
[http://dx.doi.org/10.1016/j.mce.2017.05.001] [PMID: 28526240]
[36]
Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: A case-control study. Eur J Dermatol 2017; 27(4): 382-5.
[http://dx.doi.org/10.1684/ejd.2017.3025] [PMID: 28468736]
[37]
Cummings SR, Tripp MK, Herrmann NB. Approaches to the prevention and control of skin cancer. Cancer Metastasis Rev 1997; 16(3/4): 309-27.
[http://dx.doi.org/10.1023/A:1005804328268] [PMID: 9433642]
[38]
Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J. UV-induced squamous cell carcinoma - a role for antiapoptotic signalling pathways. Br J Dermatol 2009; 161(s3) (Suppl. 3): 107-15.
[http://dx.doi.org/10.1111/j.1365-2133.2009.09458.x] [PMID: 19775366]
[39]
Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: Accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156(s3) (Suppl. 3): 1-7.
[http://dx.doi.org/10.1111/j.1365-2133.2007.07861.x] [PMID: 17488399]
[40]
Urbach F, Forbes PD, Davies RE, Berger D. Cutaneous photobiology: Past, present and future. J Invest Dermatol 1976; 67(1): 209-24.
[http://dx.doi.org/10.1111/1523-1747.ep12513042] [PMID: 778294]
[41]
Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41(1): 45-60.
[http://dx.doi.org/10.1016/j.ejca.2004.10.016] [PMID: 15617990]
[42]
Miligi L. Ultraviolet radiation exposure: Some observations and considerations, focusing on some italian experiences, on cancer risk, and primary prevention. Environments 2020; 7(2): 10.
[http://dx.doi.org/10.3390/environments7020010]
[43]
Tyrrell RM. Induction of pyrimidine dimers in bacterial DNA by 365 nm radiation. Photochem Photobiol 1973; 17(1): 69-73.
[http://dx.doi.org/10.1111/j.1751-1097.1973.tb06334.x] [PMID: 4568994]
[44]
Kong Y, Jiang J, Huang Y, et al. Endoplasmic reticulum stress in melanoma pathogenesis and resistance. Biomed Pharmacother 2022; 155: 113741.
[http://dx.doi.org/10.1016/j.biopha.2022.113741] [PMID: 36271543]
[45]
Kavasi RM, Neagu M, Constantin C, et al. Matrix effectors in the pathogenesis of keratinocyte-derived carcinomas. Front Med 2022; 9: 879500.
[http://dx.doi.org/10.3389/fmed.2022.879500] [PMID: 35572966]
[46]
Bald T, Quast T, Landsberg J, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014; 507(7490): 109-13.
[http://dx.doi.org/10.1038/nature13111] [PMID: 24572365]
[47]
Mohammad T, Morrison H, HogenEsch H. Urocanic acid photochemistry and photobiology. Photochem Photobiol 1999; 69(2): 115-35.
[http://dx.doi.org/10.1111/j.1751-1097.1999.tb03264.x] [PMID: 10048307]
[48]
Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell 2016; 29(6): 783-803.
[http://dx.doi.org/10.1016/j.ccell.2016.05.005] [PMID: 27300434]
[49]
Walko G, Woodhouse S, Pisco AO, et al. A genome-wide screen identifies YAP/WBP2 interplay conferring growth advantage on human epidermal stem cells. Nat Commun 2017; 8(1): 14744.
[http://dx.doi.org/10.1038/ncomms14744] [PMID: 28332498]
[50]
Howard A, Bojko J, Flynn B, Bowen S, Jungwirth U, Walko G. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers. Exp Dermatol 2022; 31(10): 1477-99.
[http://dx.doi.org/10.1111/exd.14655] [PMID: 35913427]
[51]
Gallagher RP, Bajdik CD, Fincham S, et al. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 1996; 5(6): 419-24.
[PMID: 8781736]
[52]
Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett 2012; 327(1-2): 48-60.
[http://dx.doi.org/10.1016/j.canlet.2011.12.012] [PMID: 22182453]
[53]
Asgari MM, Kiviat NB, Critchlow CW, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008; 128(6): 1409-17.
[http://dx.doi.org/10.1038/sj.jid.5701227] [PMID: 18185530]
[54]
Bavinck JNB, Plasmeijer EI, Feltkamp MCW. β-papillomavirus infection and skin cancer. J Invest Dermatol 2008; 128(6): 1355-8.
[http://dx.doi.org/10.1038/jid.2008.123] [PMID: 18478011]
[55]
Aldabagh B, Angeles JGC, Cardones AR, Arron ST. Cutaneous squamous cell carcinoma and human papillomavirus: Is there an association? Dermatol Surg 2013; 39(1): 1-23.
[http://dx.doi.org/10.1111/j.1524-4725.2012.02558.x] [PMID: 22928516]
[56]
Lan YJ, Chen H, Chen JQ, Lei QH, Zheng M, Shao ZR. Immunolocalization of vimentin, keratin 17, Ki-67, involucrin, β- catenin and E-cadherin in cutaneous squamous cell carcinoma. Pathol Oncol Res 2014; 20(2): 263-6.
[http://dx.doi.org/10.1007/s12253-013-9690-5] [PMID: 23999979]
[57]
Shen J, Abel EL, Riggs PK, et al. Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice. Carcinogenesis 2012; 33(11): 2208-19.
[http://dx.doi.org/10.1093/carcin/bgs213] [PMID: 22782996]
[58]
Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154(3): 498-504.
[http://dx.doi.org/10.1111/j.1365-2133.2005.07021.x] [PMID: 16445782]
[59]
Yesantharao P, Wang W, Ioannidis NM, Demehri S, Whittemore AS, Asgari MM. Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system. Hum Immunol 2017; 78(4): 327-35.
[http://dx.doi.org/10.1016/j.humimm.2017.02.002] [PMID: 28185865]
[60]
Glover MT, Brown J, Navarrete C, et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1993; 29(4): 520-4.
[http://dx.doi.org/10.1016/S0959-8049(05)80143-1] [PMID: 8435203]
[61]
Chen AC, Halliday GM, Damian DL. Non-melanoma skin cancer: Carcinogenesis and chemoprevention. Pathology 2013; 45(3): 331-41.
[http://dx.doi.org/10.1097/PAT.0b013e32835f515c] [PMID: 23478234]
[62]
Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005; 571(1-2): 185-205.
[http://dx.doi.org/10.1016/j.mrfmmm.2004.06.059] [PMID: 15748647]
[63]
Schwarz A, Noordegraaf M, Maeda A, Torii K, Clausen BE, Schwarz T. Langerhans cells are required for UVR-induced immunosuppression. J Invest Dermatol 2010; 130(5): 1419-27.
[http://dx.doi.org/10.1038/jid.2009.429] [PMID: 20090769]
[64]
Florence MEB, Massuda JY, Bröcker EB, Metze K, Cintra ML, de Souza EM. Angiogenesis in the progression of cutaneous squamous cell carcinoma: An immunohistochemical study of endothelial markers. Clinics (São Paulo) 2011; 66(3): 465-8.
[http://dx.doi.org/10.1590/S1807-59322011000300018] [PMID: 21552674]
[65]
Paulitschke V, Gerner C, Hofstätter E, et al. Proteome profiling of keratinocytes transforming to malignancy. Electrophoresis 2015; 36(4): 564-76.
[http://dx.doi.org/10.1002/elps.201400309] [PMID: 25395074]
[66]
Villiotou V, Deliconstantinos G. Nitric oxide, peroxynitrite and nitroso-compounds formation by ultraviolet A (UVA) irradiated human squamous cell carcinoma: Potential role of nitric oxide in cancer prognosis. Anticancer Res 1995; 15(3): 931-42.
[PMID: 7544092]
[67]
Maeda A, Nakata M, Yasuda K, et al. Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis. Oncol Rep 2013; 29(1): 39-44.
[http://dx.doi.org/10.3892/or.2012.2075] [PMID: 23064377]
[68]
Ruiz MT, Biselli PM, Maniglia JV, Pavarino-Bertelli EC, Goloni-Bertollo EM. Genetic variability of vascular endothelial growth factor and prognosis of head and neck cancer in a Brazilian population. Braz J Med Biol Res 2010; 43(2): 127-33.
[http://dx.doi.org/10.1590/S0100-879X2009007500036] [PMID: 20098841]
[69]
Guo D, Wang Q, Li C, Wang Y, Chen X. VEGF stimulated the angiogenesis by promoting the mitochondrial functions. Oncotarget 2017; 8(44): 77020-7.
[http://dx.doi.org/10.18632/oncotarget.20331] [PMID: 29100366]
[70]
Woo YR, Cho SH, Lee JD, Kim HS. The human microbiota and skin cancer. Int J Mol Sci 2022; 23(3): 1813.
[http://dx.doi.org/10.3390/ijms23031813] [PMID: 35163734]
[71]
Wood DLA, Lachner N, Tan JM, et al. A natural history of actinic keratosis and cutaneous squamous cell carcinoma microbiomes. MBio 2018; 9(5): e01432-18.
[http://dx.doi.org/10.1128/mBio.01432-18] [PMID: 30301852]
[72]
Nakatsuji T, Chen TH, Butcher AM, et al. A commensal strain of Staphylococcus epidermidis protects against skin neoplasia. Sci Adv 2018; 4(2): eaao4502.
[http://dx.doi.org/10.1126/sciadv.aao4502] [PMID: 29507878]
[73]
Glatthardt T, Campos JCM, Chamon RC, et al. Small molecules produced by commensal Staphylococcus epidermidis disrupt formation of biofilms by Staphylococcus aureus. Appl Environ Microbiol 2020; 86(5): e02539-19.
[http://dx.doi.org/10.1128/AEM.02539-19] [PMID: 31862721]
[74]
Li H, Goh BN, Teh WK, et al. Skin commensal Malassezia globosa secreted protease attenuates Staphylococcus aureus biofilm formation. J Invest Dermatol 2018; 138(5): 1137-45.
[http://dx.doi.org/10.1016/j.jid.2017.11.034] [PMID: 29246799]
[75]
Haenssle HA, Fink C, Schneiderbauer R, et al. Man against machine: Diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Ann Oncol 2018; 29(8): 1836-42.
[http://dx.doi.org/10.1093/annonc/mdy166] [PMID: 29846502]
[76]
Khan MQ, Hussain A, Rehman SU, et al. Classification of melanoma and nevus in digital images for diagnosis of skin cancer. IEEE Access 2019; 7: 90132-44.
[http://dx.doi.org/10.1109/ACCESS.2019.2926837]
[77]
Kousis I, Perikos I, Hatzilygeroudis I, Virvou M. Deep learning methods for accurate skin cancer recognition and mobile application. Electronics (Basel) 2022; 11(9): 1294.
[http://dx.doi.org/10.3390/electronics11091294]
[78]
Poser I, Tatzel J, Kuphal S, Bosserhoff AK. Functional role of MIA in melanocytes and early development of melanoma. Oncogene 2004; 23(36): 6115-24.
[http://dx.doi.org/10.1038/sj.onc.1207797] [PMID: 15208686]
[79]
Rawson RV, Vergara IA, Stretch JR, et al. Representativeness of initial skin biopsies showing pure desmoplastic melanoma: Implications for management. Pathology 2023; 55(2): 214-22.
[http://dx.doi.org/10.1016/j.pathol.2022.12.346] [PMID: 36646575]
[80]
Hogarty DT, Su JC, Phan K, et al. Artificial intelligence in dermatology-where we are and the way to the future: A review. Am J Clin Dermatol 2020; 21(1): 41-7.
[http://dx.doi.org/10.1007/s40257-019-00462-6] [PMID: 31278649]
[81]
Jahn AS, Navarini AA, Cerminara SE, et al. Over-detection of melanoma-suspect lesions by a CE-certified smartphone app: Performance in comparison to dermatologists, 2D and 3D convolutional neural networks in a prospective data set of 1204 pigmented skin lesions involving patients’ perception. Cancers (Basel) 2022; 14(15): 3829.
[http://dx.doi.org/10.3390/cancers14153829] [PMID: 35954491]
[82]
Pawlik L, Morgenroth S, Dummer R. Recent progress in the diagnosis and treatment of melanoma and other skin cancers. Cancers (Basel) 2023; 15(6): 1824.
[http://dx.doi.org/10.3390/cancers15061824] [PMID: 36980709]
[83]
Żółkiewicz J, Sławińska M, Maińska U, Nowicki RJ, Sobjanek M, Thomas L. Dermoscopy of umbilical lesions-A systematic review. J Clin Med 2024; 13(6): 1790.
[http://dx.doi.org/10.3390/jcm13061790] [PMID: 38542014]
[84]
Farady I, Furqon EN, Kuo C-C, Jan Y-K, Lin C-Y. Pseudo Skin Image Generator (PSIG-Net): Ambiguity-free sample generation and outlier control for skin lesion classification. Biomed Signal Process Control 2024; 93: 106112.
[http://dx.doi.org/10.1016/j.bspc.2024.106112]
[85]
Schuh S, Ruini C, Perwein MKE, et al. Line-field confocal optical coherence tomography: A new tool for the differentiation between nevi and melanomas? Cancers (Basel) 2022; 14(5): 1140.
[http://dx.doi.org/10.3390/cancers14051140] [PMID: 35267448]
[86]
Viegas J, Sarmento B. Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research. Adv Drug Deliv Rev 2024; 208: 115295.
[http://dx.doi.org/10.1016/j.addr.2024.115295] [PMID: 38527625]
[87]
Trager MH, Geskin LJ, Samie FH, Liu L. Biomarkers in melanoma and non-melanoma skin cancer prevention and risk stratification. Exp Dermatol 2022; 31(1): 4-12.
[http://dx.doi.org/10.1111/exd.14114] [PMID: 32415889]
[88]
Bosserhoff AK. Melanoma inhibitory activity (MIA): An important molecule in melanoma development and progression. Pigment Cell Res 2005; 18(6): 411-6.
[http://dx.doi.org/10.1111/j.1600-0749.2005.00274.x] [PMID: 16280006]
[89]
Vučetić B, Rogan SA, Hrabač P, et al. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res 2008; 18(3): 201-7.
[http://dx.doi.org/10.1097/CMR.0b013e3283021929] [PMID: 18477894]
[90]
Shalhout SZ, Kaufman HL, Emerick KS, Miller DM. Immunotherapy for nonmelanoma skin cancer: Facts and hopes. Clin Cancer Res 2022; 28(11): 2211-20.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-2971] [PMID: 35121622]
[91]
Carreira B, Acúrcio RC, Matos AI, et al. Nanomedicines as multifunctional modulators of melanoma immune microenvironment. Adv Ther (Weinh) 2021; 4(1): 2000147.
[http://dx.doi.org/10.1002/adtp.202000147]
[92]
Azhar F, Naureen H, Shahnaz G, et al. Development of chitosan based β-carotene mucoadhesive formulation for skin cancer treatment. Int J Biol Macromol 2023; 253(Pt 1): 126659.
[http://dx.doi.org/10.1016/j.ijbiomac.2023.126659] [PMID: 37660856]
[93]
Conforti C, Corneli P, Harwood C, Zalaudek I. Evolving role of systemic therapies in non-melanoma skin cancer. Clin Oncol (R Coll Radiol) 2019; 31(11): 759-68.
[http://dx.doi.org/10.1016/j.clon.2019.08.011] [PMID: 31522944]
[94]
Tagliaferri L, Ciardo FG. Non-melanoma skin cancer treated by contact high-dose-rate radiotherapy (brachytherapy): A mono-institutional series and literature review. In Vivo 2021; 35(4): 2313-9.
[http://dx.doi.org/10.21873/invivo.12505] [PMID: 34182511]
[95]
McDaniel WE. Therapy for basal cell epitheliomas by curettage only. Further study. Arch Dermatol 1983; 119(11): 901-3.
[http://dx.doi.org/10.1001/archderm.1983.01650350029009] [PMID: 6639109]
[96]
Kauvar ANB, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: Squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 2015; 41(11): 1214-40.
[http://dx.doi.org/10.1097/DSS.0000000000000478] [PMID: 26445288]
[97]
Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin. J Photochem Photobiol B 1990; 6(1-2): 143-8.
[http://dx.doi.org/10.1016/1011-1344(90)85083-9] [PMID: 2121931]
[98]
Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma: Results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140(1): 17-23.
[http://dx.doi.org/10.1001/archderm.140.1.17] [PMID: 14732655]
[99]
Suárez-Valladares MJ, Rodriguez-Prieto MÁ, Serra-Llusà R. Penetration of 630 nm laser and 5-aminolevulinic acid in tissue with intralesional photodynamic therapy. Photodiagn Photodyn Ther 2016; 16: 166-8.
[http://dx.doi.org/10.1016/j.pdpdt.2016.09.006] [PMID: 27645917]
[100]
Lui H, Hobbs L, Tope WD, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: Two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004; 140(1): 26-32.
[http://dx.doi.org/10.1001/archderm.140.1.26] [PMID: 14732656]
[101]
Dąbrowski JM, Arnaut LG. Photodynamic therapy (PDT) of cancer: From local to systemic treatment. Photochem Photobiol Sci 2015; 14(10): 1765-80.
[http://dx.doi.org/10.1039/c5pp00132c] [PMID: 26219737]
[102]
Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma. Br J Dermatol 2008; 159(1): 137-44.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08593.x] [PMID: 18489606]
[103]
Griffin L, Lear J. Photodynamic therapy and non-melanoma skin cancer. Cancers (Basel) 2016; 8(10): 98.
[http://dx.doi.org/10.3390/cancers8100098] [PMID: 27782094]
[104]
Jalian HR, Avram MM, Stankiewicz KJ, Shofner JD, Tannous Z. Combined 585 nm pulsed-dye and 1,064 nm Nd:YAG lasers for the treatment of basal cell carcinoma. Lasers Surg Med 2014; 46(1): 1-7.
[http://dx.doi.org/10.1002/lsm.22201] [PMID: 24272664]
[105]
Soleymani T, Abrouk M, Kelly KM. An analysis of laser therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2017; 43(5): 615-24.
[http://dx.doi.org/10.1097/DSS.0000000000001048] [PMID: 28195845]
[106]
Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014; 32(8): 745-51.
[http://dx.doi.org/10.1200/JCO.2013.49.9525] [PMID: 24493717]
[107]
Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high- risk cutaneous squamous cell carcinoma: Clinical experience and review of literature. World J Surg Oncol 2011; 9(1): 80.
[http://dx.doi.org/10.1186/1477-7819-9-80] [PMID: 21771334]
[108]
Benkhaled S, Van Gestel D, Gomes da Silveira Cauduro C, Palumbo S, Marmol V, Desmet A. The state of the art of radiotherapy for non-melanoma skin cancer: A review of the literature. Front Med 2022; 9: 913269.
[http://dx.doi.org/10.3389/fmed.2022.913269] [PMID: 35833108]
[109]
Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373(17): 1618-26.
[http://dx.doi.org/10.1056/NEJMoa1506197] [PMID: 26488693]
[110]
Abramson AK, Krasny MJ, Goldman GD. Tangential shave removal of basal cell carcinoma. Dermatol Surg 2013; 39(3): 387-92.
[http://dx.doi.org/10.1111/dsu.12106] [PMID: 23279298]
[111]
Ghareeb ER, Dulmage BO, Vargo JA, Balasubramani GK, Beriwal S. Underutilization of Mohs micrographic surgery for less common cutaneous malignancies in the United States. Dermatol Surg 2016; 42(5): 653-62.
[http://dx.doi.org/10.1097/DSS.0000000000000705] [PMID: 27054447]
[112]
Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg 2013; 15(5): 337-43.
[http://dx.doi.org/10.1001/jamafacial.2013.1011] [PMID: 23744451]
[113]
Krähn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001; 37(2): 251-9.
[http://dx.doi.org/10.1016/S0959-8049(00)00364-6] [PMID: 11166154]
[114]
Amaral T, Garbe C. Non-melanoma skin cancer: New and future synthetic drug treatments. Expert Opin Pharmacother 2017; 18(7): 689-99.
[http://dx.doi.org/10.1080/14656566.2017.1316372] [PMID: 28414587]
[115]
Micali G, Lacarrubba F, Nasca MR, Ferraro S, Schwartz RA. Topical pharmacotherapy for skin cancer: Part II. Clinical applications. J Am Acad Dermatol 2014; 70(6): 979.
[116]
Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-Fluorouracil. J Cutan Med Surg 2003; 7(2): 101-5.
[http://dx.doi.org/10.1177/120347540300700201] [PMID: 12447619]
[117]
Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. Eur J Cancer 2019; 118: 10-34.
[http://dx.doi.org/10.1016/j.ejca.2019.06.003] [PMID: 31288208]
[118]
Danial C, Sarin KY, Oro AE, Chang ALS. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res 2016; 22(6): 1325-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1588] [PMID: 26546616]
[119]
Cortes JE, Douglas Smith B, Wang ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 2018; 93(11): 1301-10.
[http://dx.doi.org/10.1002/ajh.25238] [PMID: 30074259]
[120]
Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: Is there a therapeutic role for elective neck dissection? Dermatol Surg 2007; 33(4): 410-20.
[http://dx.doi.org/10.1097/00042728-200704000-00003] [PMID: 17430374]
[121]
Agrawal AD. Pharmacological activities of flavonoids: A review. Int J Pharm Sci Nanotechnol 2011; 4(2): 1394-8.
[http://dx.doi.org/10.37285/ijpsn.2011.4.2.3]
[122]
Saeidnia S, Abdollahi M. Antioxidants: Friends or foe in prevention or treatment of cancer: The debate of the century. Toxicol Appl Pharmacol 2013; 271(1): 49-63.
[http://dx.doi.org/10.1016/j.taap.2013.05.004] [PMID: 23680455]
[123]
Stahl W, Sies H. Bioactivity and protective effects of natural carotenoids. Biochim Biophys Acta Mol Basis Dis 2005; 1740(2): 101-7.
[http://dx.doi.org/10.1016/j.bbadis.2004.12.006] [PMID: 15949675]
[124]
Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. Molecules 2012; 17(3): 3202-42.
[http://dx.doi.org/10.3390/molecules17033202] [PMID: 22418926]
[125]
Lee JH, Kishikawa M, Kumazoe M, Yamada K, Tachibana H. Vitamin A enhances antitumor effect of a green tea polyphenol on melanoma by upregulating the polyphenol sensing molecule 67-kDa laminin receptor. PLoS One 2010; 5(6): e11051.
[http://dx.doi.org/10.1371/journal.pone.0011051] [PMID: 20548792]
[126]
Feskanich D, Willett WC, Hunter DJ, Colditz GA. Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women. Br J Cancer 2003; 88(9): 1381-7.
[http://dx.doi.org/10.1038/sj.bjc.6600882] [PMID: 12778065]
[127]
Uddin AN, Labuda I, Burns FJ. A novel mechanism of filaggrin induction and sunburn prevention by β-damascenone in Skh-1 mice. Toxicol Appl Pharmacol 2012; 265(3): 335-41.
[http://dx.doi.org/10.1016/j.taap.2012.08.035] [PMID: 22982537]
[128]
Delmas D, Lançon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr Drug Targets 2006; 7(4): 423-42.
[http://dx.doi.org/10.2174/138945006776359331] [PMID: 16611030]
[129]
Qiu Y, Yu T, Wang W, Pan K, Shi D, Sun H. Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. Biochem Biophys Res Commun 2014; 448(1): 15-21.
[http://dx.doi.org/10.1016/j.bbrc.2014.04.024] [PMID: 24735534]
[130]
Hamsa TP, Thejass P, Kuttan G. Induction of apoptosis by sulforaphane in highly metastatic B16F-10 melanoma cells. Drug Chem Toxicol 2011; 34(3): 332-40.
[http://dx.doi.org/10.3109/01480545.2010.538694] [PMID: 21649489]
[131]
Davids LM, Kleemann B, Kacerovská D, Pizinger K, Kidson SH. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B 2008; 91(2-3): 67-76.
[http://dx.doi.org/10.1016/j.jphotobiol.2008.01.011] [PMID: 18342534]
[132]
Zhang H, Samadi AK, Cohen MS, Timmermann BN. Antiproliferative withanolides from the Solanaceae: A structure–activity study. Pure Appl Chem 2012; 84(6): 1353-67.
[http://dx.doi.org/10.1351/PAC-CON-11-10-08] [PMID: 24098060]
[133]
Mandlik Ingawale DS, Namdeo AG. Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl 2021; 18(2): 183-226.
[http://dx.doi.org/10.1080/19390211.2020.1741484] [PMID: 32242751]
[134]
Greay S, Ireland D. Induction of necrosis and cell cycle arrest in murine cancer cell lines by Melaleuca alternifolia (tea tree) oil and terpinen-4-ol. Chemother Pharmacol 2010; 65: 877-88.
[135]
Nigam N, Bhui K, Prasad S, George J, Shukla Y. [6]-Gingerol induces reactive oxygen species regulated mitochondrial cell death pathway in human epidermoid carcinoma A431 cells. Chem Biol Interact 2009; 181(1): 77-84.
[http://dx.doi.org/10.1016/j.cbi.2009.05.012] [PMID: 19481070]
[136]
Yoon TJ, Yoo YC, Kang TB, et al. Antitumor activity of the Korean Mistletoe Lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res 2003; 26(10): 861-7.
[http://dx.doi.org/10.1007/BF02980033] [PMID: 14609136]
[137]
Ukiya M, Akihisa T, Yasukawa K, Tokuda H, Suzuki T, Kimura Y. Anti-inflammatory, anti-tumor-promoting, and cytotoxic activities of constituents of marigold (Calendula officinalis) flowers. J Nat Prod 2006; 69(12): 1692-6.
[http://dx.doi.org/10.1021/np068016b] [PMID: 17190444]
[138]
Ngo SNT, Williams DB, Head RJ. Rosemary and cancer prevention: Preclinical perspectives. Crit Rev Food Sci Nutr 2011; 51(10): 946-54.
[http://dx.doi.org/10.1080/10408398.2010.490883] [PMID: 21955093]
[139]
Debnath S, Kumar S, Chandu AN, Bhattacharjee C. Cytotoxicity study of plant Aloe vera (Linn). Chron Young Sci 2012; 3(3): 233-5.
[http://dx.doi.org/10.4103/2229-5186.99595]
[140]
Priestap HA, Galvis A, Rivero N, Costantino V, Lopez LA, Barbieri MA. Dehydroleucodine and dehydroparishin-B inhibit proliferation and motility of B16 melanoma cells. Phytochem Lett 2012; 5(3): 581-5.
[http://dx.doi.org/10.1016/j.phytol.2012.05.018]
[141]
Lee CC, Chiu CC, Liao WT, et al. Alpinia oxyphylla Miq. bioactive extracts from supercritical fluid carbon dioxide extraction. Biochem Eng J 2013; 78: 101-7.
[http://dx.doi.org/10.1016/j.bej.2013.03.009]
[142]
Lo CY, Liu PL, Lin LC, et al. Antimelanoma and antityrosinase from Alpinia galangal constituents. ScientificWorldJournal 2013; 2013: 1-5.
[http://dx.doi.org/10.1155/2013/186505] [PMID: 24027439]
[143]
Uzzaman S. Pharmacological activities of neem (Azadirachta indica): A review. Int J Pharmacog Life Sci 2020; 1(1): 38-41.
[http://dx.doi.org/10.33545/27072827.2020.v1.i1a.8]
[144]
Nagini S, Nivetha R, Palrasu M, Mishra R. Nimbolide, a neem limonoid, is a promising candidate for the anticancer drug arsenal. J Med Chem 2021; 64(7): 3560-77.
[http://dx.doi.org/10.1021/acs.jmedchem.0c02239] [PMID: 33739088]
[145]
Dhama K, Sharun K, Gugjoo MB, et al. A comprehensive review on chemical profile and pharmacological activities of Ocimum basilicum. Food Rev Int 2023; 39(1): 119-47.
[http://dx.doi.org/10.1080/87559129.2021.1900230]
[146]
Ahmad B, Hafeez N, Rauf A, et al. Phyllanthus emblica: A comprehensive review of its therapeutic benefits. Front Pharmacol 2021; 138: 278-310.
[147]
Santha S, Dwivedi C. Anticancer effects of sandalwood (Santalum album). Anticancer Res 2015; 35(6): 3137-45.
[PMID: 26026073]
[148]
Tiwari P, Nayak P, Prusty SK, Sahu PK. Phytochemistry and pharmacology of Tinospora cordifolia: A review. Syst Rev Pharm 2018; 9(1): 70-8.
[http://dx.doi.org/10.5530/srp.2018.1.14]
[149]
Burgeiro A, Bento AC, Gajate C, Oliveira PJ, Mollinedo F. Rapid human melanoma cell death induced by sanguinarine through oxidative stress. Eur J Pharmacol 2013; 705(1-3): 109-18.
[http://dx.doi.org/10.1016/j.ejphar.2013.02.035] [PMID: 23499690]
[150]
Goldberg LH, Landau JM, Moody MN, Vergilis-Kalner IJ. Treatment of Bowen’s disease on the penis with low concentration of a standard mixture of solasodine glycosides and liquid nitrogen. Dermatol Surg 2011; 37(6): 858-61.
[http://dx.doi.org/10.1111/j.1524-4725.2011.02014.x] [PMID: 21605251]
[151]
Soliman E, Henderson KL, Danell AS, Van Dross R. Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: Role of cyclooxygenase-2 and novel J-series prostamides. Mol Carcinog 2016; 55(2): 117-30.
[http://dx.doi.org/10.1002/mc.22257] [PMID: 25557612]
[152]
Blázquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006; 20(14): 2633-5.
[http://dx.doi.org/10.1096/fj.06-6638fje] [PMID: 17065222]
[153]
Dheeraj A, Rigby CM, O’Bryant CL, et al. Silibinin treatment inhibits the growth of Hedgehog inhibitor-resistant basal cell carcinoma cells via targeting EGFR-MAPK-Akt and Hedgehog signaling. Photochem Photobiol 2017; 93(4): 999-1007.
[http://dx.doi.org/10.1111/php.12727] [PMID: 28120452]
[154]
Berlanda J, Kiesslich T, Oberdanner CB, Obermair FJ, Krammer B, Plaetzer K. Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol 2006; 25(1-2): 173-88.
[http://dx.doi.org/10.1615/JEnvironPatholToxicolOncol.v25.i1-2.100] [PMID: 16566716]
[155]
Gupta N, Gupta GD, Singh D. Localized topical drug delivery systems for skin cancer: Current approaches and future prospects. Front Nanotechnol 2022; 4: 1006628.
[http://dx.doi.org/10.3389/fnano.2022.1006628]
[156]
Shah K, Date A, Joshi M, Patravale V. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int J Pharm 2007; 345(1-2): 163-71.
[http://dx.doi.org/10.1016/j.ijpharm.2007.05.061] [PMID: 17644288]
[157]
Ravikumar P, Tatke P. Advances in encapsulated dermal formulations in chemoprevention of melanoma: An overview. J Cosmet Dermatol 2019; 18(6): 1606-12.
[http://dx.doi.org/10.1111/jocd.13105] [PMID: 31436386]
[158]
Slominski AT, Brożyna AA, Zmijewski MA, et al. Vitamin D signaling and melanoma: Role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97(6): 706-24.
[http://dx.doi.org/10.1038/labinvest.2017.3] [PMID: 28218743]
[159]
Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015; 49(8): 907-37.
[http://dx.doi.org/10.1177/1060028015586218] [PMID: 25991832]
[160]
Weinstein D, Leininger J, Hamby C, Safai B. Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol 2014; 7(6): 13-24.
[PMID: 25013535]
[161]
Vennepureddy A, Thumallapally N, Nehru VM, Atallah JP, Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res 2016; 8(2): 63-75.
[http://dx.doi.org/10.14740/jocmr2424w] [PMID: 26767073]
[162]
Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J 2012; 18(2): 192-202.
[http://dx.doi.org/10.1097/PPO.0b013e31824f118b] [PMID: 22453021]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy